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Adequate surgical management of primary melanoma and regional lymph node metastasis, and rarely distant
metastasis, is the only established curative treatment. Surgical management of primary melanomas consists of
excisions with 1–2 cm margins and primary closure. The recommended method of biopsy is excisional biopsy with a
2 mm margin and a small amount of subcutaneous fat. In speciﬁc situations (very large lesions or certain anatomical
areas), full-thickness incisional or punch biopsy may be acceptable. Sentinel lymph node biopsy provides accurate
staging information for patients with clinically unaffected regional nodes and without distant metastases, although
survival beneﬁt has not been proved. In cases of positive sentinel node biopsy or clinically detected regional nodal
metastases (palpable, positive cytology or histopathology), radical removal of lymph nodes of the involved basin is
indicated. For resectable local/in-transit recurrences, excision with a clear margin is recommended. For numerous or
unresectable in-transit metastases of the extremities, isolated limb perfusion or infusion with melphalan should be
considered. Decisions about surgery of distant metastases should be based on individual circumstances.
Radiotherapy is indicated as a treatment option in select patients with lentigo maligna melanoma and as an adjuvant in
select patients with regional metastatic disease. Radiotherapy is also indicated for palliation, especially in bone and
brain metastases.
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introduction
Surgery remains the mainstay of melanoma therapy at all sites.
Early diagnosis combined with appropriate surgical therapy is
currently the only curative treatment. Ideally, surgery should
provide both local control of the disease and long-term survival
without signiﬁcant functional and/or aesthetic impairment.
The aim of this article is to present updated recommendations
on surgical management of melanoma.
surgery of primary tumour
biopsy
Skin lesions that might be melanoma should be referred using
the ABCDE system (A, asymmetry; B, irregular borders; C,
colour changes; D, diameter >5 mm; E, elevation) or the
Glasgow system [1]. However, >50% of melanomas are de novo
lesions that may not have any of the characteristics listed above.
Clinical diagnosis can be improved by non-invasive
epiluminescence microscopy (dermatoscopy) [2].
Excision biopsy is essential for accurate diagnosis and
microstaging. This determines the choice of further therapy and
provides important prognostic information. The pathology
report should include the Breslow thickness (mm), presence of
ulceration, mitotic index (0 or ‡1/mm
2), Clark level, lateral and
deep margin size (mm) and the presence of local metastasis.
Mitotic index is the third most important independent
prognostic factor [3, 4], and will be introduced in the new
AJCC staging system as a reporting standard. Regression,
tumour-inﬁltrating lymphocytes, vertical growth phase,
angiolymphatic invasion, neurotropism and histologic subtype
may also be of value.
Excision biopsy is usually performed with a 2 mm lateral
margin and a cuff of subdermal fat. Incisional or punch biopsy
may be performed for lesions that are difﬁcult to remove
because of size or site. It is believed not to have detrimental
effects if subsequent therapeutic surgery is performed within
4–6 weeks. Shave or curette-type biopsies should not be
performed because they limit the amount and quality of
specimen for pathological assessment. The initial biopsy scar
should not compromise subsequent surgery; on the limb, it
should be oriented along the long axis.
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Before the 1970s, margins of therapeutic excision ranged from
3t o>5 cm. However, since then, six randomised, prospective
trials (Table 1) have evaluated the effect of width of excision
margins on local recurrence rates and survival. Rates of local
control have been similar in ﬁve of these studies, but one has
shown a 25% increase in locoregional recurrence in patients
with narrow margins. None have shown a survival disadvantage
for narrower compared with wider radial excision margins in
melanoma of any thickness, although most were not powered
to detect this, and one has shown a trend toward reduced
survival [5–7].
Three trials were conducted for melanomas thinner than
2 mm: the French Cooperative Group Trial [8] and the
Scandinavian Melanoma Group Study [9] compared 2 cm with
5 cm margins, and the World Health Organization (WHO)
Melanoma Program Trial 10 compared 1 cm and 3 cm margins
[10]. None of these trials demonstrated a beneﬁt for wider
margins (Table 1).
For melanomas of intermediate thickness (1–4 mm), 486
patients in the Intergroup Trial [11, 12] were randomised to
2 cm or 4 cm margins. Local recurrence rates (2.1% compared
with 2.6%, respectively) and overall survival (OS) rates were
similar (79% compared with 81%, respectively). In the group of
patients with 2 cm margins, skin grafts were necessary in
only 11% of cases, as compared with 46% of cases in the group
with 4 cm margins (P < 0.001). Two large trials were
conducted in patients with melanomas thicker than 2 mm: the
UK Melanoma Study Group (MSG) trial of 900 patients
compared 1 cm and 3 cm margins and the Scandinavian trial of
936 patients compared 2 cm and 4 cm margins [13, 14].
In the UK MSG trial, OS was similar in both groups,
although a 25% higher rate of locoregional recurrence was
noted in the group with the narrow margin [hazard ratio (HR)
1.26, P = 0.05]. The Scandinavian trial, which randomised
patients with melanomas >2.0 mm (pT3, pT4) between 2 cm
and 4 cm margins, reported no differences in outcome for
disease-free survival (DFS) or OS [5, 14].
There are fewer data for melanomas thicker than 4 mm, since
disease in this thickness band is uncommon. A large, but non-
randomised study [15] showed that excisions with margins
wider than 2 cm do not have any impact on local recurrence
rates, DFS and OS. The UK MSG and Scandinavian studies
included patients with melanomas >4 mm [13, 14].
For melanoma not thicker than 1 mm, excisions with a 1 cm
margin are sufﬁcient. Recommendations about 1–2 mm thick
invasive melanoma are less clear; however, many national
guidelines indicate that a 1–2 cm margin is sufﬁcient, especially
in regions of anatomic constraint associated with anticipated
functional or cosmetic deformities (e.g. face, distal part of
limbs). For melanomas >2 mm, a 2 cm margin is appropriate.
In all surgical trials of primary melanoma, depth of excision has
always been to at least muscle fascia, and this is the
recommended deep margin, since more superﬁcial excision has
not been shown to be equivalent. Deeper excision has not been
shown to improve outcome [16, 17].
In summary, this means that in general, surgical
management of primary melanoma consists of excision and
primary closure.
special melanoma types
In certain subgroups of patients, recommendations on excision
margins are based only on opinion.
For melanoma in situ, the recommended margin is 0.5 cm.
Although thought to have no risk of metastasis, it can recur as
in situ and then progress to invasive melanoma, and some data
indicate that 1 cm margins may be required [18, 19].
Wider margins have been recommended for desmoplastic
melanoma because of its increased tendency toward local
recurrence. If this is due to contiguous subclinical spread,
micrographically controlled excision may reduce risk. Margin
size should probably be determined by tumour thickness [19].
technical aspects
The long axis of the excision should be in the direction of the
lymphatic drainage and parallel to the long axis of the limb.
This decreases the risk of lymphoedema (especially in the case
of subsequent lymph node dissection). Primary closure without
dog ears usually requires that the longest axis of an elliptical
incision be at least three times longer than the short axis.
Table 1. Clinical trials on surgical margins of radical excision in primary melanoma
Clinical study
a Patients (no.) Thickness (mm)
b Margins (cm) Overall survival (%) Ref.
French Cooperative Group 336 £2 2 or 5 87/86 (10-year) [8]
Swedish Melanoma Group 989 £2 2 or 5 90/93 (5-year) [9]
WHO Melanoma Group Trial No. 10 612 £2 1 or 3 87/87 (10-year) [10]
Intergroup Melanoma Surgical Trial 486 1–4 2 or 4 80/82 (6-year) [11, 12]
UK Melanoma Study Group 900 ‡2 1 or 3 Not reported; hazard
ratio for death was
similar in both
groups (5-year)
[13]
Swedish Melanoma Trial Group 1000 >2 2 or 4 Final results not
reported; preliminary
results indicated no
differences (5-year)
[14]
aOverall survival was not statistically signiﬁcant.
bBreslow.
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not including, the underlying muscle fascia. The majority of
wounds with 1–2 cm margins of excision can be closed
primarily. Split skin grafting or local random-pattern ﬂaps are
used in a minority of cases. Full-thickness grafts are commonly
used on the face or hands for better aesthetic and cosmetic
results and may be taken from behind the ear, from the
supraclavicular or inguinal region, or from a site of sentinel
node biopsy (SNB). Free-tissue transfer with microvascular
reconstruction is used mainly for extensive disease on the head
and neck. Mohs’ micrographic surgery is not appropriate for
treating primary melanoma, since the purpose of this is
removal of local micrometastases, which, by deﬁnition, are
discontiguous from the primary lesion. Mohs’ surgery may be
useful for extensive contiguous disease such as large, clinically
ill-deﬁned in situ melanoma of the lentigo maligna type, and
possibly desmoplastic melanoma.
primary melanoma at speciﬁc sites
Melanoma on the palms and soles, nail unit, and head and neck
should probably be treated as usual on the basis of tumour
thickness. Patients with such lesions have generally been
excluded from surgical trials. There are few adequate data on
surgical margins and adjuvant chemoradiotherapy for mucosal
and anogenital melanoma.
Mucosal and anogenital melanoma. Primary melanoma located
on mucosal surfaces represents <3% of all melanoma but is
aggressive, with only 20% of patients alive at 5 years [20].
Among mucosal sites, the most frequent are the head and neck
(‡50%), female genital tract (mostly vulva, 20%) and anorectal
region (20%) [20, 21]. The rarest are primary melanomas
originating from the urinary tract sites and stomach/bowel.
Early detection is unlikely because of the occult anatomic
locations.
The diagnosis must be established after a full thickness
biopsy of the suspicious lesion with the exception of small
lesions suitable for excisional biopsy. Incisional biopsy should
include a representative sample from the border of the lesion to
help the pathologist in differentiating a primary mucosal
melanoma from mucosal melanoma metastasis.
Head and neck mucosal melanoma affects mainly the nasal
and oral cavity. The primary approach to treatment of mucosal
melanoma is wide surgical resection; however, 5-year OS is
only 13–22% [22, 23]. While many cases of mucosal melanoma
are treated with surgery alone, radiotherapy or chemotherapy
as an adjuvant therapy or even the only modality
(radiotherapy) is employed more frequently than in cutaneous
melanoma, although the beneﬁt of this is unclear. The most
frequent primary site of genital melanoma is the vulva [24];
there is a high incidence of local and distant metastasis.
Multiple studies of more than 350 cases of vulvar melanoma
indicated that radical vulvectomy (with or without
lymphadenectomy) does not improve OS and DFS compared
with more limited resection (wide local excision or partial
vulvectomy) [25–27]. Radical vulvectomy, in contrast to wide
local excision, is associated with very high morbidity and is not
recommended. Most cases of melanoma of the penis are treated
by amputation [28]. In genital melanoma, staging with SNB
may be considered. The majority of melanoma of the anorectal
region arises below the dentate line in the squamous mucosa,
and so often presents late. No signiﬁcant differences between
abdominoperineal resection and local excision either in OS or
DFS have been found [29]. The procedure of choice is a wide
local excision with histologically clear margins (ultrasound can
be helpful in delineating lesions) that avoids permanent
colostomy.
Subungual melanoma. Subungual melanoma accounts for <1%
of tertiary referral cases [30]. Amputation of a ﬁnger or a toe
can only be considered. Distal, function-preserving
amputations or even non-amputational approaches are now the
usual practice [31].
Melanoma of the face and scalp. For melanoma of the face,
normal excision margins may have to be compromised to
preserve aesthetic features and functions. There are no data to
quantify any adverse outcome of this practice [32]. Melanoma
of the ear is treated by wedge excision, or by partial or complete
pinnectomy, depending on tumour thickness and patient
preference for reconstruction or prosthesis.
Lentigo maligna and lentigo maligna melanoma. Lentigo
maligna (LM) is a type of in-situ melanoma, and occurs on the
head and neck usually in patients >50 years old. Risk of
progression to invasive lentigo maligna melanoma (LMM) is
well recognised but poorly quantiﬁed. Lesions may grow to
5–10 cm or larger. Biopsy is prone to sampling error and may
incorrectly indicate benign disease or miss early invasion.
Clinical deﬁnition may be poor but can be helped by
illumination under a Wood’s light. The surgical margin
required for LM has not been conﬁrmed by any randomised
controlled trial: 5 mm or more is usual and gives cure rates of
90–95% [33]. A recent retrospective study of 117 cases of LM
and LMM treated with a staged, margin-controlled excision
technique found that a mean total surgical margin required for
excision of LMM was 10.3 mm [33]. However, it is difﬁcult to
distinguish between LM melanocytes and atypical melanocytes
on sun-exposed skin. Orthovoltage radiotherapy using 7–10
mm margins can give cure rates similar to surgery, but there are
fewer data to support this and it is generally only suitable when
surgery is not feasible [34].
surgery of regional lymph nodes
sentinel node biopsy
In the last 10 years, the experimental procedure of SNB has
been increasingly used. This technique replaced elective lymph
node dissection, a method previously recommended for early
Table 2. Recommendations for margins of primary melanoma excision
based on tumour thickness
Tumour thickness
(Breslow)
Recommended deﬁnitive
margin of excision
In situ 0.5 cm
£2.0 mm 1.0 cm
>2.0 mm 2.0 cm
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several randomised trials (WHO-1 and WHO-14, Mayo
Clinical Surgical Trial and Intergroup Melanoma Surgical Trial
[35–40]) and signiﬁcant morbidity. SNB allows identiﬁcation of
the ﬁrst draining lymph node; if positive for melanoma,
subsequent completion lymphadenectomy might improve
survival. The Melanoma Selective Lymphadenectomy Trial
(MSLT-I) [41] was designed to test this idea. The study
conﬁrmedthevalueofSNBasastagingprocedure[42],butfailed
todetectadifferenceinsurvivalbetweenpatientsintheSNBwith
early lymphadenectomy cohort and those treated later after
clinically detected lymph node relapse. However, the 5-year
survival rate of a subgroup of patients with intermediate-
thickness melanoma (1.2–3.5 mm) (72.3% compared with
52.4%, respectively) did appear to be increased by SNB and early
lymphadenectomy. The 5-year survival rate for sentinel node
(SN)-negative patients was 90.2 6 1.3% [41]. An ongoing
MSLT-II study is designed to test whether completion
lymphadenectomy is required in patients with a positive SNB.
Lymphoscintigraphy and lymphatic mapping is an essential
part of the SNB procedure, since lymphatic drainage cannot be
accurately predicted [43, 44]. Lymphoscintigraphy provides
topographic information about the number of lymph node
basin(s) and SN(s). One day or 2–4 h before surgery, dynamic
lymphoscintigraphy is performed by intradermal injection of
99mTc-labelled colloid particles of human serum albumin (as
lymphoscint, nanocoll or albu-Res) into both sides of the
melanoma excision scar. Different types and doses of labelled
solution can be injected; we recommend the use of
99mTc-
labelled colloids with 10–200 nm particles. For trunk, and head
and neck, an anterior–posterior view and a lateral view must
be obtained to localise all SNs [45]. If only one lymphatic basin
is involved in the axilla or groin, SNB may be feasible under
local anaesthesia, but in the neck or popliteal fossa, or when
multiple basins are involved, it is generally better to operate under
general anaesthesia. Following lymphoscintigraphy and 10 min
after intradermal injection of Vital Blue dye into the same
point(s) as the colloid, the surgical procedure can be conducted.
Vital Blue should never be used in the head and neck because of
the risk of leaving a permanent tattoo on a visible part of the skin
[ 4 6 ] ,o rd u r i n gp r e g n a n c y .D u r i n gt h eS N Bp r o c e d u r e ,ac-
detector probe (cDP) is used to track the radiolabelled tracer
towards a single or multiple SNs. This permits a safe, minimal
dissection towards the SN. If no vital dye is visible, the cDP
should be used immediately after the incision of the superﬁcial
fascia in order to reduce the surgical dissection. Devices with
intraoperative c detector in association with intraoperative c
camera have recently reached the market and this way keep
conﬁrming that the percentage of SNs detected approaches 100%.
SNB provides accurate staging information, but at present is
not known to have any therapeutic value. It is generally used
in patients with primary melanomas ‡1.0 mm in thickness,
although some investigators question its utility in melanomas
thicker than 4 mm. Ulceration, Clark IV and V, mitotic rate per
mm
2 and patients choice can also be considered for melanomas
<1 mm Breslow thickness.
Histopathology of the sentinel node. The histopathology of the
SN is crucial, and the extent of the procedure determines the
positivity rate [47–49]. Topography of the SNB metastases [50,
51], and their volume, determine prognosis [52]. Metastases
<0.1 mm have only a 2% positivity rate for non-SN on
completion lymphadenectomy and the same DFS, distant
metastasis-free survival and OS rates as SN-negative patients
[52, 53]. However, increasing size of the metastases in the SNB
is associated with increasing risk of a positive completion
lymphadenectomy and reduced survival.
therapeutic lymph node dissection
The most frequently affected basins are the neck, axilla and
groin; involvement of popliteal fossa or epitrochlear lymph
nodes is rare. Lymphadenectomy for melanoma has two goals:
it may be curative, or it may simply prevent further relapse
at that site. Both can only be achieved by meticulous and
thorough removal of all involved and at-risk nodes. In general,
this means dissection of all ﬁve levels of lymph nodes in the
neck plus superﬁcial parotidectomy if the primary site is
thought to drain to parotid nodes, all three levels in the axilla,
and the superﬁcial, deep inguino-femoral and ilio-obturator
nodes. Pelvic lymph nodes should always be included if
enlarged on preoperative imaging.
Although no convincing data support selective
lymphadenectomy, in clinical practice some compromises are
sometimes made. For example, when the metastases lie in the
posterior triangle nodes (level 5), submandibular (level 1) nodes
mightbeconserved.Theilio-obturatornodesmightnotbeexcised
unless clinically involved [54], although the greater the burden of
superﬁcialinguinaldiseasethegreatertheriskoftheirinvolvement.
Some carry out a frozen section examination of Cloquet’s node
during the inguinal–femoral dissection; if positive, a deep pelvic
dissection is carried out, although a negative Cloquet’s node does
notguaranteenegativepelvicnodes.Thedissectionofpelvicnodes
does not increase long-term post operative complications. These
are decisions made on the basis of opinion and experience, and
should only be made by melanoma specialists.
surgery of locoregional recurrences
local metastases
The terminology of metastasis between the primary melanoma
and draining lymph nodes is confusing, inconsistently deﬁned
and unhelpful. In adequately treated primary melanoma, the
terms localrecurrence, local metastasis, in-transit metastasis and
satellite metastasis are all likely to reﬂect the same biological
process of intralymphatic spread beyond the site of therapeutic
excision [55]. Since all are characterised by poor prognosis, they
should be treated similarly, and are best collectively referred to
asin-transitmetastases(ITM).Itisimportanttopointoutthatin
primary melanoma where adequate surgical treatment has not
been carried out, recurrence of melanoma in or adjacent to the
scar might represent regrowth of residual primary disease
rather than metastasis. In this situation it would be wise to treat
the lesion as a thick primary melanoma, since this might offer a
chance of cure.
in-transit metastases
Prevention: prophylactic isolated limb perfusion. Early adjuvant
treatment of high-risk primary limb melanoma with regional
Annals of Oncology
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improve survival. Although retrospective studies of isolated limb
perfusion (ILP) with melphalan indicated improved outcome
in high-risk primary melanoma, a prospective randomised study
of wide excision compared with wide excision plus adjuvant ILP
in 832 patients [56] did not show any beneﬁt. Rates of
progression to systemic metastases and OS were unchanged with
only a small improvement in locoregional control.
Treatment of apparent in-transit metastases. Treatment of ITM
of the limb depends on their number, site and size [57].
Resectable ITM should be treated surgically with narrow but
clear margins. Amputation is not indicated and does not
improve survival. With multiple dermal ITM, carbon dioxide
laser ablation can be used, but the recurrence rate is very high
and this technique is limited to lesions <1 cm in diameter.
Other local modalities including radiotherapy, cryotherapy,
intralesional injections and electrochemotherapy may be used
in speciﬁc situations. Regional chemotherapy with ILP or
isolated limb infusion (ILI) is the preferred method of treating
multiple and frequently recurrent ITM. It treats the whole limb
below the point of tourniquet isolation, can achieve 20–50
times higher concentrations of melphalan compared with
systemic therapy, and can be performed with minimal
locoregional toxicity and minimal systemic leakage [58]. ILP
with melphalan can be used in combination with tumour
necrosis factor (TNF)-a [59, 60], especially in the case of bulky
lesions [60, 61] or after failure of a prior ILP or ILI using
melphalan alone [62, 63]. Iliac ILP has the advantage of treating
the whole limb up to the groin; ILI only treats to the upper
third of the thigh. ILI is probably slightly less effective than ILP,
but is less invasive and easier to repeat.
Electrochemotherapy can be indicated for palliation of
superﬁcial metastatic lesions when ILP or ILI is not indicated
for the general conditions of the patient; a 90% response on the
superﬁcial metastases has been reported [64, 65].
surgery of distant metastases
The purpose of treatment of distant metastases is palliation.
Surgery is the most effective means of providing this if it is
technically feasible, if risk of morbidity and mortality is low and
if the patient is likely to live long enough to accrue beneﬁt. A
positron emission tomography scan may be used to conﬁrm the
ﬁnding of computed tomography scanning of a locoregional or
distant lesion that is surgically treatable. Good examples are
single or localised metastases to the brain, bowel, lung or spinal
cord. After careful consideration it may be reasonable to resect
a single or localised liver metastasis. Completely resected single
distant metastases may occasionally be associated with long
survival [66, 67]. More common examples are symptomatic
soft-tissue metastases. No prospective study compares surgical
with medical approaches to treatment of melanoma patients
with a single or very few distant metastases.
radiotherapy
Radiotherapy (RT) is a cancer treatment modality that
contributes to the cure or palliation of cancer patients.
Cutaneous melanoma has long been considered a relatively
radioresistant tumour, due to a distinctly broad shoulder in the
low-dose portion of the survival curve [68].
Early studies in melanoma demonstrated that the response
rate depended on the size of the dose per fraction; complete
response rates were 82% (range 67–92%) for fractions of >4 Gy,
but only 36% (range 21–46%) for those of <4 Gy [69–73].
However, recent studies on cell lines show characteristics
similar to those of acutely and late-responding normal tissue
with a broad variation of intrinsic radiosensitivity [74, 75].
The only randomised study that evaluated the effectiveness of
the high-dose-per-fraction irradiation in the treatment of
melanoma was planned by the Radiation Therapy Oncology
Group (RTOG) in 1983. One hundred and thirty-seven patients
without abdominal or brain metastases and with 50% of the
lesions >5 cm were randomised to four fractions of 8 Gy or 20
fractions of 2.5 Gy. In both arms, the overall and complete
response rates were 59% and 24%, respectively [76].
Conventional fractionation schedules should be preferred, since
they are equally effective in tumour control. In some situations,
such as palliation of bone metastases or relief of metastatic
lesions in patients with a short life expectancy, a larger dose per
fraction is more convenient.
primary melanoma
Surgical resection has proved effective at low risk, so
radiotherapy is not a primary treatment for invasive cutaneous
melanoma. Radiotherapy should be considered in lentigo
maligna, especially in elderly patients with extensive or
unresectable disease [33, 69]. It has not been shown to be
effective in lentigo maligna melanoma. It may also be used in
desmoplastic melanoma, but only when adequate surgical
margins are not obtainable [70, 71]. No data support the utility
of adjuvant radiotherapy in other forms of cutaneous
melanoma. It may rarely be used by melanoma specialists in the
presence of positive or close margins where re-resection is
difﬁcult to carry out, and local failure could jeopardise the
probability of cure.
Radiotherapy can be successfully used in the treatment of
mucosal melanoma of the nasal cavity and paranasal sinuses. In
contrast to other forms of mucosal melanoma, lesions of the
head and neck have the tendency to fail locally before systemic
spread, and a radical resection is often difﬁcult to achieve in
these regions.
In mucosal melanomas, primary radiotherapy techniques
lead to regression rates of 80% [77, 78]. Postoperative
radiotherapy looks more efﬁcacious than surgery alone [79,
80], and some authors consider surgery with postoperative
radiotherapy a current standard of treatment for malignant
mucosal melanoma of the head and neck [81]. However,
prospective randomised trials are needed in the adjuvant setting
in order to assess the real impact of radiotherapy on local
control, quality of life and OS.
regional lymph nodes
The regional recurrence rate after lymph node dissection can be
as high as 20–50% [72]. Many factors have been related to an
increased risk of regional recurrence including the number of
Annals of Oncology
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and the presence of extracapsular extension, which remains the
single most important risk factor for relapse. Regional
recurrence in the dissected lymph node basin may become
unmanageable and can have a serious adverse impact on quality
of life and survival. Several phase II studies observed an increase
in locoregional control (87–95%) after irradiation with 30–36
Gy in ﬁve or six fractions or 50–60 Gy in 25–30 fractions,
depending on the site, risk and patient [73, 82–86]. The only
published, randomised study, which used 50 Gy in 28 fractions,
ﬁve fractions/week, found no effect of postoperative
radiotherapy on either OS or DFS [87]. The cohort of patients,
however, was insufﬁcient to detect small differences in survival
and was not stratiﬁed for signiﬁcant prognostic variables. Two
recently planned randomised studies [RTOG and the Eastern
Cooperative Oncology Group (ECOG)] have been aborted for
lack of sufﬁcient accrual, but two other studies, sponsored by
the Trans-Tasman Radiation Oncology Group and the Mofﬁtt
Cancer Center, are still open and recruiting patients. Although
published data remain sparse, American and Australian
guidelines recommend postoperative adjunct irradiation in
patients with stage III melanoma at high risk of relapse
(www.nci.nih.gov, www.health.gov.au, www.nccn.org).
disseminated and recurrent melanoma
Radiotherapy has an important role in the palliation of many
symptoms in melanoma patients. A short course of
radiotherapy is generally preferred, and good palliation can be
obtained in approximately two-thirds of cases; however, the
exact degree of the tumour response depends greatly on the
tumour size at the time of irradiation [76, 77, 88]. Pain relief
and/or decompression in 67% of patients with bone metastases
and good palliation in 80–85% of similarly treated patients
have been reported using 30 Gy in 10 fractions or 20 Gy in 5
fractions [78, 79, 89]. The overall response rate reported with
different fractional doses ranges from 9% to 92%, with
a median of 50% [80, 81, 88]. The same percentage was
achieved in the RTOG 83-05 randomised study, conﬁrming
that radiotherapy represents still the best palliation whenever
surgery is not applicable.
brain metastasis
Brain (CNS) metastases affect 10–40% of melanoma patients in
clinical studies and represent a sharp decrease in quality of life
and survival. CNS is the ﬁrst site of recurrence in 15–20% of
patients with stage IV melanoma. In the majority of patients
with multiple lesions, surgery is rarely indicated, and
chemotherapy alone is largely ineffective [90]. The median
survival in untreated patients has been reported to be as low as
1 month [91], and despite early detection of frequently
asymptomatic metastatic disease using conventional imaging
modalities, the prognosis remains poor with reported median
survival ranging from 2 to 8 months.
Multiple brain metastases. The median survival of symptomatic
patients with multiple brain lesions treated with anti-oedema
therapy (corticosteroids and osmotic diuretics) is only 2
months and can be extended to 4–6 months after whole-brain
radiation therapy (WBRT). With both treatments, 60–70% of
patients experience improvement in neurological symptoms
and performance status with no signiﬁcant differences between
various conventional fractionation schemes (20 Gy in 5
fractions, 30 Gy in 10 fractions, 40 Gy in 20 fractions) [92];
however, the procedure is not without morbidity (hair loss,
brain oedema, lethargy, cognitive impairment).
Single or few brain metastases. Treatment options for patients
with just one or a few, smaller brain metastases include
neurosurgical resection and stereotactic irradiation. The
feasibility of resection depends on the lesions’ number, size and
location, neurologic symptoms and deﬁcits, and also on the
presence of extracranial disease, age and performance status.
Patients with multiple, but resectable brain lesions may have
a prognosis similar to that of patients with solitary brain lesions
[93] and may beneﬁt from surgical resection of a symptomatic
or life-threatening brain lesion [94]. Surgery followed by
WBRT improved survival compared with WBRT alone [95, 96].
Stereotactic radiosurgery (SRS) is a highly effective local
treatment of brain metastases that provides targeted high-dose
irradiation of one to six lesions with a diameter not exceeding
3–4 cm, in a single or multiple sessions [97]. Recent
publications indicate that its efﬁcacy using either multiple
cobalt sources (gamma-knife) or a linear accelerator (Linac) is
similar to that of surgical resection. The reported local control
rates from uncontrolled studies range from 80% to 96% with
a median survival in the range 7–12 months; however, in
patients with multiple lesions, median survival decreases to 4
months [98]. Adjuvant WBRT was found to decrease the
distant brain failure in SRS-treated patients from 64% to 17%
after 6 months [99].
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